Cambridge Investment Research Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.14M | Buy |
45,749
+17,327
| +61% | +$1.45M | 0.01% | 1153 |
|
|
2026
Q1 | $2.28M | Sell |
28,422
-3,798
| -12% | -$313K | 0.01% | 1499 |
|
|
2025
Q4 | $2.75M | Buy |
32,220
+5,690
| +21% | +$467K | 0.01% | 1286 |
|
|
2025
Q3 | $2.06M | Sell |
26,530
-1,935
| -7% | -$151K | 0.01% | 1484 |
|
|
2025
Q2 | $2.23M | Buy |
28,465
+6
| +0% | +$447 | 0.01% | 1354 |
|
|
2025
Q1 | $2.06M | Sell |
28,459
-5,382
| -16% | -$385K | 0.01% | 1316 |
|
|
2024
Q4 | $2.5M | Sell |
33,841
-2,513
| -7% | -$176K | 0.01% | 1198 |
|
|
2024
Q3 | $2.4M | Buy |
36,354
+7,254
| +25% | +$527K | 0.01% | 1212 |
|
|
2024
Q2 | $2.69M | Sell |
29,100
-5,117
| -15% | -$453K | 0.01% | 1092 |
|
|
2024
Q1 | $3.27M | Sell |
34,217
-6
| -0% | -$504 | 0.01% | 985 |
|
|
2023
Q4 | $2.61M | Sell |
34,223
-5,169
| -13% | -$360K | 0.01% | 1034 |
|
|
2023
Q3 | $2.73M | Buy |
39,392
+1,011
| +3% | +$81.2K | 0.01% | 961 |
|
|
2023
Q2 | $3.62M | Sell |
38,381
-1,442
| -4% | -$125K | 0.02% | 825 |
|
|
2023
Q1 | $3.29M | Sell |
39,823
-64
| -0.2% | -$5.03K | 0.02% | 839 |
|
|
2022
Q4 | $2.98M | Sell |
39,887
-1,358
| -3% | -$105K | 0.02% | 866 |
|
|
2022
Q3 | $3.41M | Sell |
41,245
-1,308
| -3% | -$126K | 0.02% | 746 |
|
|
2022
Q2 | $4.05M | Sell |
42,553
-1,967
| -4% | -$204K | 0.02% | 680 |
|
|
2022
Q1 | $5.24M | Sell |
44,520
-2,928
| -6% | -$328K | 0.02% | 611 |
|
|
2021
Q4 | $6.15M | Sell |
47,448
-446
| -0.9% | -$52K | 0.03% | 565 |
|
|
2021
Q3 | $5.42M | Sell |
47,894
-8,587
| -15% | -$980K | 0.03% | 574 |
|
|
2021
Q2 | $5.85M | Buy |
+56,481
| New | +$5.32M | 0.03% | 548 |
|
|
2021
Q1 | – | Sell |
-63,203
| Closed | -$5.77M | – | 2902 |
|
|
2020
Q4 | $5.77M | Sell |
63,203
-12,335
| -16% | -$1.02M | 0.03% | 473 |
|
|
2020
Q3 | $6.03M | Buy |
75,538
+4,447
| +6% | +$347K | 0.04% | 407 |
|
|
2020
Q2 | $4.91M | Buy |
71,091
+10,977
| +18% | +$780K | 0.04% | 446 |
|
|
2020
Q1 | $3.78M | Sell |
60,114
-876
| -1% | -$63.2K | 0.04% | 454 |
|
|
2019
Q4 | $4.74M | Buy |
60,990
+9,756
| +19% | +$762K | 0.04% | 488 |
|
|
2019
Q3 | $3.76M | Buy |
51,234
+84
| +0.2% | +$5.9K | 0.03% | 528 |
|
|
2019
Q2 | $3.15M | Sell |
51,150
-7,509
| -13% | -$454K | 0.03% | 558 |
|
|
2019
Q1 | $3.74M | Buy |
58,659
+4,209
| +8% | +$240K | 0.04% | 470 |
|
|
2018
Q4 | $2.78M | Buy |
54,450
+5,304
| +11% | +$268K | 0.03% | 522 |
|
|
2018
Q3 | $2.85M | Buy |
49,146
+14,790
| +43% | +$723K | 0.03% | 562 |
|
|
2018
Q2 | $1.67M | Buy |
34,356
+585
| +2% | +$27.3K | 0.02% | 721 |
|
|
2018
Q1 | $1.57M | Sell |
33,771
-1,482
| -4% | -$64.4K | 0.02% | 722 |
|
|
2017
Q4 | $1.32M | Sell |
35,253
-3,804
| -10% | -$140K | 0.02% | 768 |
|
|
2017
Q3 | $1.42M | Buy |
39,057
+1,068
| +3% | +$40.7K | 0.02% | 668 |
|
|
2017
Q2 | $1.5M | Buy |
+37,989
| New | +$1.39M | 0.02% | 624 |
|
|
2016
Q4 | – | Sell |
-51,093
| Closed | -$2.05M | – | 1752 |
|
|
2016
Q3 | $2.05M | Buy |
+51,093
| New | +$1.92M | 0.04% | 424 |
|
|
2016
Q2 | – | Sell |
-36,345
| Closed | -$1.07M | – | 1626 |
|
|
2016
Q1 | $1.07M | Buy |
36,345
+9,555
| +36% | +$264K | 0.02% | 544 |
|
|
2015
Q4 | $705K | Buy |
+26,790
| New | +$696K | 0.02% | 695 |
|
|
2015
Q3 | – | Sell |
-24,030
| Closed | -$570K | – | 1511 |
|
|
2015
Q2 | $570K | Buy |
24,030
+8,454
| +54% | +$191K | 0.02% | 745 |
|
|
2015
Q1 | $370K | Buy |
15,576
+810
| +5% | +$18.2K | 0.01% | 945 |
|
|
2014
Q4 | $313K | Buy |
14,766
+1,284
| +10% | +$25.8K | 0.01% | 1000 |
|
|
2014
Q3 | $230K | Buy |
+13,482
| New | +$213K | 0.01% | 1226 |
|
Other funds holding EW
Cambridge Investment Research Advisors's EW Position: Q2 2026 in Review
Cambridge Investment Research Advisors increased its Edwards Lifesciences (EW) stake by 61% in Q2 2026, buying an estimated $1.45M and bringing the position to 45,749 shares worth $4.14M. The position accounts for 0.01% of the portfolio, ranked #1153.
Cambridge Investment Research Advisors first reported a position in EW in Q3 2014 and has held it in 43 quarters since. The position peaked at $6.15M in Q4 2021. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Cambridge Investment Research Advisors held 45,749 shares of Edwards Lifesciences worth $4.14M as of Q2 2026.
- Cambridge Investment Research Advisors bought 17,327 Edwards Lifesciences shares in Q2 2026, an estimated $1.45M.
- Edwards Lifesciences made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1153 holding.
- Cambridge Investment Research Advisors first reported a position in Edwards Lifesciences in Q3 2014 and has held it in 43 quarters since.
- Cambridge Investment Research Advisors's Edwards Lifesciences position peaked at $6.15M in Q4 2021.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.